Trials Sponsors Conditions Drugs Pricing

Conditions

Dermatophyte Infection

Keywords

TineaVoriconazoleDermatomycosesAntifungal Agents

Outcome Measures

Primary Outcomes (1)

Efficacy of oral voriconazole 200 mg once daily(low dose) vs. twice daily (high dose)
Efficacy will be assesssed clinically either through complete resolution of lesion or leaving behind pigmentation
Clinical assessment for efficacy will be done at day 14 and day 28

Study Arms (2)

oral voriconazole 200 mg once daily group (group A)

ACTIVE COMPARATOR

Patients with resistant dermatophyte infection (tinea corporis and cruris)will be given oral voriconazole 200 mg once daily

Drug: Voriconazole low dose

oral voriconazole 200 mg twice daily group (group B)

ACTIVE COMPARATOR

Patients with resistant dermatophyte infection (tinea corporis and cruris)will be given oral voriconazole 200 mg twice daily

Drug: Voriconazole high dose

Interventions

Voriconazole high doseDrug

Oral voriconazole 200mg once a day for a maximum of 28 days

oral voriconazole 200 mg twice daily group (group B)

Voriconazole low doseDrug

Oral voriconazole 200mg twice a day for a maximum of 28 days

oral voriconazole 200 mg once daily group (group A)

Eligibility Criteria

Age18 Years - 60 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64)

You may qualify if:

Resistant cases of tinea cruris and tinea corporis: Those cases who received the standard dosage of oral antifungals i.e. oral terbinafine 5mg/kg per day for 4 weeks or oral itraconazole 5mg per/kg/day for 4 weeks but they did not recover from the infection.
Skin area: Groin and trunk

Sponsors & Collaborators

Sheikh Zayed Medical College
Governmentlead

Study Sites (1)

Sheikh zayed Medical College and Hospital

Rahim Yar Khan, Punjab Province, 64200, Pakistan

Sheikh zayed Medical college SZMC/HCONTACT+92689230168 info@szmc.edu.pk

MeSH Terms

Conditions

DermatomycosesTinea

Interventions

Voriconazole

Condition Hierarchy (Ancestors)

MycosesBacterial Infections and MycosesInfectionsSkin Diseases, InfectiousSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

TriazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Central Study Contacts

Muhammad Khurram Shahzad, FCPS dermatology

CONTACT

+923354847957 dr.khuram178@gmail.com

Tahir Hassan Hassan, FCPS Dermatology

CONTACT

+923364192737

Study Design

Study Type: interventional
Phase: phase 2
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: OTHER GOV
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Senior Registrar Dermatology

Study Record Dates

First Submitted

November 6, 2024

First Posted

November 8, 2024

Study Start

November 15, 2024

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Primary Completion

March 1, 2025

Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

oral voriconazole 200 mg once daily group (group A)

oral voriconazole 200 mg twice daily group (group B)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (2)

oral voriconazole 200 mg once daily group (group A)

oral voriconazole 200 mg twice daily group (group B)

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations